TABLE 1. FAMILY RECRUITMENTa

 

 MaleFemaleTotal
 
Population-based families*     8745
Case probandsb 4213 4265 8479
Affected relativesb 570 565 1135
Unaffected relativesc 13048 15186 28234
Control probandsc 2057 2199 4256
Relatives of Controls (Australia site only) 2130 2132 4262
Total population-based individuals 22935 25487 48423
 
Clinic-based families**     1861
Affected probandsb 625 584 1209
Unaffected probandsc 119 279 398
Affected relativesb 1140 1027 2167
Unaffected relativesc 5292 5920 11212
Total clinic-based individuals 7227 7863 15090
 

 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.

 

 

 


TABLE 2. AVAILABLE RESOURCES

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 5476 5573 11050
  Proxy family history/epi data 934 770 1704
  1st Follow-up epi data 3193 3542 6736
  2nd Follow-up epi data 1393 1615 3009
  FFQ datae 2605 2905 5511
  Blood/buccal samples 5150 5211 10362
  EBV-transformed lymphoblastoid cell lines 1661 1575 3237
  Tumor material 4478 4286 8765
  Clinical Dx and Treatment info 1816 1642 3458
 
Unaffected Individualsc Family history/epi dataa,d 13794 17892 31686
  Proxy family history/epi data 9260 8279 17539
  1st Follow-up epi data 8438 11387 19825
  2nd Follow-up epi data 3687 5204 8891
  FFQ datae 6631 8853 15484
  Blood/buccal samples 9946 13502 23448
  EBV-transformed lymphoblastoid cell lines 1082 1066 2148
  Clinical Dx and Treatment info 44 52 96
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 4062 4164 8227
  1st Follow-up epi data 2369 2669 5039
  2nd Follow-up epi data 1032 1192 2225
  FFQ datae 1998 2262 4261
  Blood/buccal samples 3780 3835 7616
  EBV-transformed lymphoblastoid cell lines 1309 1201 2511
  Tumor material 3195 3087 6283
  Clinical Dx and Treatment info 1487 1371 2858
Relativesc Family history/epi baseline dataa 13383 15442 28825
  1st Follow-up epi data 5492 7672 13164
  2nd Follow-up epi data 2732 3805 6537
  FFQ datae 3260 4634 7894
  Blood/buccal samples 5443 7715 13158
  EBV-transformed lymphoblastoid cell lines 197 299 496
  Tumor material 368 381 749
  Clinical Dx and Treatment info 70 59 129
Control Probandsd Family history/epi baseline dataa 2057 2199 4256
  1st Follow-up epi data 614 529 1143
  FFQ datae 1141 1020 2161
  Blood/buccal samples 1398 1494 2892
  EBV-transformed lymphoblastoid cell lines 723 551 1274
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 1725 1576 3301
  1st Follow-up epi data 634 658 1292
  2nd Follow-up epi data 284 327 611
  FFQ datae 432 488 920
  Blood/buccal samples 1053 1047 2100
  EBV-transformed lymphoblastoid cell lines 273 280 553
  Tumor material 993 942 1935
  Clinical Dx and Treatment info 262 216 478
Unaffected Individualsd Family history/epi baseline dataa 5391 6153 11544
  1st Follow-up epi data 2206 2966 5172
  2nd Follow-up epi data 962 1412 2374
  FFQ datae 1775 2471 4246
  Blood/buccal samples 2911 3955 6866
  EBV-transformed lymphoblastoid cell lines 107 159 266
  Clinical Dx and Treatment info 4 1 5

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 11 - Ontario

 MaleFemaleTotal
 
Population-based families*     2050
Case probandsb 915 1135 2050
Affected relativesb 67 72 139
Unaffected relativesc 1417 2035 3452
Control probandsc 1026 902 1928
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 3909 4799 8708
 
Clinic-based families**     371
Affected probandsb 75 63 138
Unaffected probandsc 16 48 64
Affected relativesb 88 80 168
Unaffected relativesc 307 426 733
Total clinic-based individuals 522 642 1164
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 11 - Ontario

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 1036 1287 2323
  Proxy family history/epi data 3 2 5
  1st Follow-up epi data 502 775 1277
  2nd Follow-up epi data 224 372 596
  FFQ datae 859 1150 2009
  Blood/buccal samples 901 1098 1999
  EBV-transformed lymphoblastoid cell lines 647 606 1253
  Tumor material 654 642 1296
  Clinical Dx and Treatment info 624 540 1164
 
Unaffected Individualsc Family history/epi dataa,d 3135 3906 7041
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 1756 2276 4032
  2nd Follow-up epi data 302 489 791
  FFQ datae 2657 3266 5923
  Blood/buccal samples 2415 3074 5489
  EBV-transformed lymphoblastoid cell lines 833 692 1525
  Clinical Dx and Treatment info 11 12 23
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 11 - Ontario

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 805 1079 1884
  1st Follow-up epi data 410 685 1095
  2nd Follow-up epi data 210 355 565
  FFQ datae 733 1028 1761
  Blood/buccal samples 711 897 1608
  EBV-transformed lymphoblastoid cell lines 590 545 1135
  Tumor material 504 494 998
  Clinical Dx and Treatment info 622 540 1162
Relativesc Family history/epi baseline dataa 1456 2127 3583
  1st Follow-up epi data 914 1393 2307
  2nd Follow-up epi data 299 493 792
  FFQ datae 1248 1806 3054
  Blood/buccal samples 1198 1771 2969
  EBV-transformed lymphoblastoid cell lines 21 39 60
  Tumor material 67 64 131
  Clinical Dx and Treatment info 2 0 2
Control Probandsd Family history/epi baseline dataa 1026 902 1928
  1st Follow-up epi data 614 528 1142
  FFQ datae 1020 897 1917
  Blood/buccal samples 746 598 1344
  EBV-transformed lymphoblastoid cell lines 694 531 1225
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 146 125 271
  1st Follow-up epi data 46 37 83
  2nd Follow-up epi data 1 1 2
  FFQ datae 51 48 99
  Blood/buccal samples 118 121 239
  EBV-transformed lymphoblastoid cell lines 47 45 92
  Tumor material 77 75 152
  Clinical Dx and Treatment info 0 0 0
Unaffected Individualsd Family history/epi baseline dataa 333 457 790
  1st Follow-up epi data 85 153 238
  2nd Follow-up epi data 2 0 2
  FFQ datae 139 217 356
  Blood/buccal samples 266 400 666
  EBV-transformed lymphoblastoid cell lines 39 38 77
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 12 - USC

 MaleFemaleTotal
 
Population-based families*     1746
Case probandsb 847 899 1746
Affected relativesb 60 59 119
Unaffected relativesc 811 1195 2006
Control probandsc 0 0 0
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 1806 2267 4073
 
Clinic-based families**     284
Affected probandsb 82 77 159
Unaffected probandsc 34 42 76
Affected relativesb 112 126 238
Unaffected relativesc 276 317 593
Total clinic-based individuals 509 573 1082
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 12 - USC

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 1092 1152 2244
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 632 708 1340
  2nd Follow-up epi data 230 250 480
  FFQ datae 700 707 1407
  Blood/buccal samples 1061 1109 2170
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 849 886 1735
  Clinical Dx and Treatment info 0 0 0
 
Unaffected Individualsc Family history/epi dataa,d 1076 1411 2487
  Proxy family history/epi data 1 0 1
  1st Follow-up epi data 769 1022 1791
  2nd Follow-up epi data 331 404 735
  FFQ datae 587 773 1360
  Blood/buccal samples 1136 1580 2716
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 12 - USC

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 845 897 1742
  1st Follow-up epi data 489 549 1038
  2nd Follow-up epi data 143 161 304
  FFQ datae 570 578 1148
  Blood/buccal samples 818 857 1675
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 625 671 1296
  Clinical Dx and Treatment info 0 0 0
Relativesc Family history/epi baseline dataa 763 1033 1796
  1st Follow-up epi data 567 778 1345
  2nd Follow-up epi data 247 293 540
  FFQ datae 471 601 1072
  Blood/buccal samples 813 1174 1987
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 61 48 109
  Clinical Dx and Treatment info 0 0 0
Control Probandsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 192 201 393
  1st Follow-up epi data 108 124 232
  2nd Follow-up epi data 68 68 136
  FFQ datae 84 92 176
  Blood/buccal samples 185 199 384
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 168 168 336
  Clinical Dx and Treatment info 0 0 0
Unaffected Individualsd Family history/epi baseline dataa 292 332 624
  1st Follow-up epi data 197 217 414
  2nd Follow-up epi data 97 125 222
  FFQ datae 111 140 251
  Blood/buccal samples 302 352 654
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 13 - Australia

 MaleFemaleTotal
 
Population-based families*     1221
Case probandsb 489 460 950
Affected relativesb 261 252 513
Unaffected relativesc 7093 7046 14139
Control probandsc 138 133 271
Relatives of Controls (Australia site only) 2130 2132 4262
Total population-based individuals 10169 10080 20250
 
Clinic-based families**     582
Affected probandsb 163 189 352
Unaffected probandsc 54 154 208
Affected relativesb 858 741 1599
Unaffected relativesc 4066 4339 8405
Total clinic-based individuals 5146 5436 10582
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 13 - Australia

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 904 914 1819
  Proxy family history/epi data 878 729 1607
  1st Follow-up epi data 630 659 1290
  2nd Follow-up epi data 318 329 648
  FFQ datae 696 755 1452
  Blood/buccal samples 889 892 1782
  EBV-transformed lymphoblastoid cell lines 179 173 353
  Tumor material 798 789 1588
  Clinical Dx and Treatment info 326 287 613
 
Unaffected Individualsc Family history/epi dataa,d 4214 5486 9700
  Proxy family history/epi data 9133 8176 17309
  1st Follow-up epi data 2978 4008 6986
  2nd Follow-up epi data 1541 2138 3679
  FFQ datae 2942 4073 7015
  Blood/buccal samples 2890 3927 6817
  EBV-transformed lymphoblastoid cell lines 57 77 134
  Clinical Dx and Treatment info 0 2 2
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 13 - Australia

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 471 441 913
  1st Follow-up epi data 345 319 665
  2nd Follow-up epi data 191 166 358
  FFQ datae 368 371 740
  Blood/buccal samples 474 440 915
  EBV-transformed lymphoblastoid cell lines 121 105 227
  Tumor material 423 401 825
  Clinical Dx and Treatment info 324 286 610
Relativesc Family history/epi baseline dataa 7297 7220 14517
  1st Follow-up epi data 1473 1933 3406
  2nd Follow-up epi data 895 1151 2046
  FFQ datae 1096 1517 2613
  Blood/buccal samples 1121 1519 2640
  EBV-transformed lymphoblastoid cell lines 8 6 14
  Tumor material 35 55 90
  Clinical Dx and Treatment info 3 2 5
Control Probandsd Family history/epi baseline dataa 138 133 271
  1st Follow-up epi data 0 1 1
  FFQ datae 121 123 244
  Blood/buccal samples 136 124 260
  EBV-transformed lymphoblastoid cell lines 29 17 46
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 1019 929 1948
  1st Follow-up epi data 263 310 573
  2nd Follow-up epi data 115 147 262
  FFQ datae 297 348 645
  Blood/buccal samples 366 397 763
  EBV-transformed lymphoblastoid cell lines 57 70 127
  Tumor material 359 376 735
  Clinical Dx and Treatment info 3 3 6
Unaffected Individualsd Family history/epi baseline dataa 4121 4503 8624
  1st Follow-up epi data 1558 2135 3693
  2nd Follow-up epi data 679 1033 1712
  FFQ datae 1525 2114 3639
  Blood/buccal samples 1705 2359 4064
  EBV-transformed lymphoblastoid cell lines 24 55 79
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 14 - Hawaii

 MaleFemaleTotal
 
Population-based families*     546
Case probandsb 312 234 546
Affected relativesb 71 41 112
Unaffected relativesc 569 780 1349
Control probandsc 0 0 0
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 998 1127 2125
 
Clinic-based families**     0
Affected probandsb 0 0 0
Unaffected probandsc 0 0 0
Affected relativesb 0 0 0
Unaffected relativesc 0 0 0
Total clinic-based individuals 0 0 0
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 14 - Hawaii

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 318 231 549
  Proxy family history/epi data 48 33 81
  1st Follow-up epi data 214 168 382
  2nd Follow-up epi data 40 40 80
  FFQ datae 269 196 465
  Blood/buccal samples 326 242 568
  EBV-transformed lymphoblastoid cell lines 75 54 129
  Tumor material 305 231 536
  Clinical Dx and Treatment info 92 66 158
 
Unaffected Individualsc Family history/epi dataa,d 457 719 1176
  Proxy family history/epi data 121 99 220
  1st Follow-up epi data 336 562 898
  2nd Follow-up epi data 140 228 368
  FFQ datae 398 623 1021
  Blood/buccal samples 454 705 1159
  EBV-transformed lymphoblastoid cell lines 29 46 75
  Clinical Dx and Treatment info 5 8 13
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 14 - Hawaii

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 296 221 517
  1st Follow-up epi data 188 157 345
  2nd Follow-up epi data 33 34 67
  FFQ datae 249 192 441
  Blood/buccal samples 292 220 512
  EBV-transformed lymphoblastoid cell lines 62 42 104
  Tumor material 279 214 493
  Clinical Dx and Treatment info 92 66 158
Relativesc Family history/epi baseline dataa 608 807 1415
  1st Follow-up epi data 336 535 871
  2nd Follow-up epi data 133 214 347
  FFQ datae 395 588 983
  Blood/buccal samples 460 678 1138
  EBV-transformed lymphoblastoid cell lines 35 48 83
  Tumor material 28 18 46
  Clinical Dx and Treatment info 0 0 0
Control Probandsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 0 0 0
  Clinical Dx and Treatment info 0 0 0
Unaffected Individualsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 15 - Mayo

 MaleFemaleTotal
 
Population-based families*     683
Case probandsb 328 355 683
Affected relativesb 72 76 148
Unaffected relativesc 604 858 1462
Control probandsc 0 0 0
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 1103 1400 2503
 
Clinic-based families**     579
Affected probandsb 297 247 544
Unaffected probandsc 6 15 21
Affected relativesb 77 74 151
Unaffected relativesc 602 779 1381
Total clinic-based individuals 987 1119 2106
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 15 - Mayo

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 756 740 1496
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 468 472 940
  2nd Follow-up epi data 229 251 480
  FFQ datae 0 0 0
  Blood/buccal samples 779 756 1535
  EBV-transformed lymphoblastoid cell lines 431 426 857
  Tumor material 817 760 1577
  Clinical Dx and Treatment info 623 585 1208
 
Unaffected Individualsc Family history/epi dataa,d 1283 1729 3012
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 841 1160 2001
  2nd Follow-up epi data 399 604 1003
  FFQ datae 0 0 0
  Blood/buccal samples 1285 1737 3022
  EBV-transformed lymphoblastoid cell lines 107 161 268
  Clinical Dx and Treatment info 26 30 56
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 15 - Mayo

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 323 350 673
  1st Follow-up epi data 206 235 441
  2nd Follow-up epi data 105 118 223
  FFQ datae 0 0 0
  Blood/buccal samples 326 354 680
  EBV-transformed lymphoblastoid cell lines 216 205 421
  Tumor material 320 348 668
  Clinical Dx and Treatment info 298 316 614
Relativesc Family history/epi baseline dataa 670 918 1588
  1st Follow-up epi data 454 660 1114
  2nd Follow-up epi data 195 314 509
  FFQ datae 0 0 0
  Blood/buccal samples 666 930 1596
  EBV-transformed lymphoblastoid cell lines 73 109 182
  Tumor material 162 173 335
  Clinical Dx and Treatment info 65 56 121
Control Probandsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 355 307 662
  1st Follow-up epi data 217 187 404
  2nd Follow-up epi data 100 111 211
  FFQ datae 0 0 0
  Blood/buccal samples 372 318 690
  EBV-transformed lymphoblastoid cell lines 169 165 334
  Tumor material 389 321 710
  Clinical Dx and Treatment info 259 213 472
Unaffected Individualsd Family history/epi baseline dataa 595 783 1378
  1st Follow-up epi data 366 461 827
  2nd Follow-up epi data 184 254 438
  FFQ datae 0 0 0
  Blood/buccal samples 605 781 1386
  EBV-transformed lymphoblastoid cell lines 44 66 110
  Clinical Dx and Treatment info 4 1 5

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 16 - Seattle

 MaleFemaleTotal
 
Population-based families*     2312
Case probandsb 1236 1081 2317
Affected relativesb 34 56 90
Unaffected relativesc 2499 3149 5648
Control probandsc 893 1164 2057
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 4804 5581 10385
 
Clinic-based families**     45
Affected probandsb 8 8 16
Unaffected probandsc 9 20 29
Affected relativesb 5 6 11
Unaffected relativesc 41 59 100
Total clinic-based individuals 63 93 156
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 16 - Seattle

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 1284 1151 2435
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 694 689 1383
  2nd Follow-up epi data 352 373 725
  FFQ datae 0 0 0
  Blood/buccal samples 1110 1011 2121
  EBV-transformed lymphoblastoid cell lines 329 316 645
  Tumor material 987 900 1887
  Clinical Dx and Treatment info 151 164 315
 
Unaffected Individualsc Family history/epi dataa,d 3582 4522 8104
  Proxy family history/epi data 0 0 0
  1st Follow-up epi data 1717 2265 3982
  2nd Follow-up epi data 974 1341 2315
  FFQ datae 0 0 0
  Blood/buccal samples 1719 2367 4086
  EBV-transformed lymphoblastoid cell lines 56 90 146
  Clinical Dx and Treatment info 2 0 2
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 16 - Seattle

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 1236 1081 2317
  1st Follow-up epi data 679 657 1336
  2nd Follow-up epi data 350 358 708
  FFQ datae 0 0 0
  Blood/buccal samples 1077 969 2046
  EBV-transformed lymphoblastoid cell lines 320 304 624
  Tumor material 977 886 1863
  Clinical Dx and Treatment info 151 163 314
Relativesc Family history/epi baseline dataa 2532 3205 5737
  1st Follow-up epi data 1706 2275 3981
  2nd Follow-up epi data 963 1340 2303
  FFQ datae 0 0 0
  Blood/buccal samples 1136 1526 2662
  EBV-transformed lymphoblastoid cell lines 60 97 157
  Tumor material 14 17 31
  Clinical Dx and Treatment info 0 1 1
Control Probandsd Family history/epi baseline dataa 893 1164 2057
  1st Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 516 772 1288
  EBV-transformed lymphoblastoid cell lines 0 3 3
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 13 14 27
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 12 12 24
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 0 2 2
  Clinical Dx and Treatment info 0 0 0
Unaffected Individualsd Family history/epi baseline dataa 50 78 128
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 33 63 96
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives
 

 


TABLE 1. FAMILY RECRUITMENTa
Center 17 - CPIC

 MaleFemaleTotal
 
Population-based families*     187
Case probandsb 86 101 187
Affected relativesb 5 9 14
Unaffected relativesc 55 123 178
Control probandsc 0 0 0
Relatives of Controls (Australia site only) 0 0 0
Total population-based individuals 146 233 379
 
Clinic-based families**     0
Affected probandsb 0 0 0
Unaffected probandsc 0 0 0
Affected relativesb 0 0 0
Unaffected relativesc 0 0 0
Total clinic-based individuals 0 0 0
 

* Includes population-based case proband families from all sites and population-based control proband families from Australia site.
** Includes all clinic-based proband families (counts family ID of affected and unaffected clinic-based probands).
 
a. Enrolled female and male individuals with completed epidemiology questionnaire and/or biospecimen (blood or buccal sample)
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection
 
Note: Blood and non-blood relatives/individuals excluding the probands.
 

 


TABLE 2. AVAILABLE RESOURCES
Center 17 - CPIC

 MaleFemaleTotal
 
Affected Individualsb Family history/epi dataa,d 86 98 184
  Proxy family history/epi data 5 6 11
  1st Follow-up epi data 53 71 124
  2nd Follow-up epi data 0 0 0
  FFQ datae 81 97 178
  Blood/buccal samples 84 103 187
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 68 78 146
  Clinical Dx and Treatment info 0 0 0
 
Unaffected Individualsc Family history/epi dataa,d 47 119 166
  Proxy family history/epi data 5 4 9
  1st Follow-up epi data 41 94 135
  2nd Follow-up epi data 0 0 0
  FFQ datae 47 118 165
  Blood/buccal samples 47 112 159
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0
 

a. Baseline data for all population-based and clinic-based individuals, males and females
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. No history of colon cancer at baseline interview or biospecimen collection; includes controls from population-based CCFR sites and unaffected clinic-based probands
d. Excluding proxy questionnaire completion
e. Food Frequency Questionnaire
 

 


TABLE 3. FAMILY DATA
Center 17 - CPIC

 MaleFemaleTotal
 
A. Population-based Colon Cancer Families
 
Case Probandsb Family history/epi baseline dataa 86 95 181
  1st Follow-up epi data 52 67 119
  2nd Follow-up epi data 0 0 0
  FFQ datae 78 93 171
  Blood/buccal samples 82 98 180
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 67 73 140
  Clinical Dx and Treatment info 0 0 0
Relativesc Family history/epi baseline dataa 57 132 189
  1st Follow-up epi data 42 98 140
  2nd Follow-up epi data 0 0 0
  FFQ datae 50 122 172
  Blood/buccal samples 49 117 166
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 1 6 7
  Clinical Dx and Treatment info 0 0 0
Control Probandsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
 
B. Clinic-based Colon Cancer Families*
 
Affected Individualsb Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Tumor material 0 0 0
  Clinical Dx and Treatment info 0 0 0
Unaffected Individualsd Family history/epi baseline dataa 0 0 0
  1st Follow-up epi data 0 0 0
  2nd Follow-up epi data 0 0 0
  FFQ datae 0 0 0
  Blood/buccal samples 0 0 0
  EBV-transformed lymphoblastoid cell lines 0 0 0
  Clinical Dx and Treatment info 0 0 0

a. Baseline data (self or proxy completion) for females and males
b. Affected with colorectal cancer at baseline interview or biospecimen collection
c. Affected and unaffected, blood and non-blood, relatives of case probands, at baseline interview or biospecimen collection. Probands excluded.
d. No history of colon cancer at baseline interview or biospecimen collection
e. Food Frequency Questionnaire
* Includes all clinic-based probands and their blood or non-blood relatives